RESEARCH / PARTICIPATIONBack to the library
← Find a study
Recruiting · registry status

Blood tests for Parkinson's and related conditions

Researchers are looking for blood markers that could help identify diseases involving the protein alpha-synuclein.

Learning by observing or collecting information · Study reference: JPRN-UMIN000062131

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.

Open the official registry record ↗

Follow this study

Results reported

Start (reported date)
2026-06-26
Study finished (reported date)
2031-03-31

Planned dates can move. A study finishing does not tell us when a paper will be published.

Read the results reported in the registry

Changes we have recorded
  • 2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Age 18years-old and over · Ask the team who can join

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: male and female

Inclusion criteria: Existing samples and data meeting either of the following criteria will be included: 1. Patients with dementia-related disorders or healthy volunteers who participated in existing QST studies, have stored blood samples at QST, and have at least one available dataset among PET, MRI, or neuropsychological assessment data. Target conditions include Parkinsons disease, dementia with Lewy bodies, Alzheimers disease, frontotemporal lobar degeneration, progressive supranuclear palsy, corticobasal syndrome, multiple system atrophy, REM sleep behavior disorder, mild cognitive impairment, and healthy controls. 2. Participants enrolled in PPMI or BioFINDER whose sample provision for this study has been approved by the sample access committee or equivalent body of each cohort. Exclusion criteria: 1. For the QST cohort, individuals who refuse secondary use of their samples or data through the opt-out procedure for this study. 2. Samples or data judged by QST investigators to be unsuitable for measurement because of sample quality, freeze-thaw history, storage duration, hemolysis, or other relevant factors. 3. For international cohorts, samples or data for which withdrawal of sample or data provision occurs according to the rules of each cohort, or samples judged to be unsuitable for measurement because of sample quality.
Full study name & original research details

Official study title

Validation of blood biomarkers for Lewy body disease through collaboration with international cohorts - LBD-BM International Validation Study

Short title used by the registry

Validation study of blood biomarkers for Lewy body disease using international cohorts

Original description

Primary outcome: Discriminative performance of blood biomarker levels, including Ac-alpha-syn, measured in existing samples for Lewy body disease. The primary assessment will include ROC-AUC, sensitivity, and specificity for distinguishing Lewy body disease, including Parkinsons disease or dementia with Lewy bodies, from non-Lewy body disease, including Alzheimers disease and healthy controls. Secondary outcome: 1. Associations between blood biomarker levels and PET imaging findings, including amyloid, tau, and alpha-synuclein PET 2. Associations between blood biomarker levels and cerebrospinal fluid biomarker levels 3. Associations between blood biomarker levels and clinical severity measures, including MDS-UPDRS, MMSE, and MoCA 4. Reproducibility of blood biomarker levels and diagnostic performance across the QST, PPMI, and BioFINDER cohorts 5. Diagnostic performance of combinations of multiple blood biomarkers

Conditions reported: Lewy body disease, including Parkinson's disease, dementia with Lewy bodies, and REM sleep behavior disorder, and related neurodegenerative disorders

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

Study type
Observational
Interventions
Not reported
Phases
Not selected
Sponsor
National Institutes for Quantum Science and Technology
Start date reported by registry
2026-06-26 (reported)

Registry updated: Not reported · Status last verified by the registry submitter: Not reported

Registry records retrieved 2026-10-11 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Kenji Tagai · 043-206-3251 · tagai.kenji@qst.go.jp

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Facility not reported

Japan

Status not reported

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.